Overview

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

This study compares the pharmacokinetics (PK), safety and tolerability of fixed dose combination (FDC) tablets containing solifenacin succinate and mirabegron with the co-administration of single entity tablets (SET), at three dose strengths.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Mirabegron
Solifenacin Succinate